Dr. Gandara Discusses Clinical Implications of the FLAURA Study in NSCLC
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discusses the significance of the phase III FLAURA trial of first-line osimertinib (Tagrisso) in EGFR-mutant non-small cell lung cancer (NSCLC).
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discusses the significance of the phase III FLAURA trial of first-line osimertinib (Tagrisso) in EGFR-mutant non—small cell lung cancer (NSCLC), during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.
The most important aspect of FLAURA is that a new-generation inhibitor can be superior to the standard first-generation standard of care in not just efficacy, but toxicity as well, Gandara explains.
Secondly, the data on patients with brain metastases highly favored osimertinib over the first-generation agents, he concludes.
